Trial Profile
Phase Ib Trial With Dose Expansion of the Bruton"s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab and Lenalidomide in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Diffuse large B cell lymphoma; Nervous system neoplasms
- Focus Adverse reactions
- 18 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 18 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 11 Aug 2022 Status changed from recruiting to active, no longer recruiting.